Pierre Legault

Pierre Legault serves as the Chairman of the Board for multiple biopharmaceutical companies, including Sitryx Therapeutics, Bicycle Therapeutics, Artios Pharma Ltd, Amolyt Pharma, and Egle Therapeutics, contributing extensive leadership experience in developing innovative therapies across various medical fields such as cancer treatments and rare diseases. Legault's board involvement extends to Syndax Pharmaceuticals and previously to Urovant Sciences and POXEL, showcasing a solid background in governance and strategic committees. With an academic foundation that includes an MBA from McGill University and an Executive Master Program from Harvard Business School, Legault combines their financial, marketing, and accounting expertise with a deep understanding of biopharmaceutical advancements.